Drug
Nogapendekin alfa inbakicept
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | Cytokine Modulators |
| Group | Cytokine Modulators |
| Mechanism of Action | IL-15 receptor agonist |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Data on this page refer exclusively to patients treated with
Nogapendekin alfa inbakicept combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Cytokine Modulators group page.